Genialis

About:

Genialis is a computational precision medicines company that develops a clinical biomarker discovery platform.

Twitter/X: genialis

Top Investors: Taiwania Capital Management Corporation, First Star Ventures, EASME - EU Executive Agency for SMEs, redalpine, Debiopharm Innovation Fund

Description:

Genialis is a computational precision medicines company that develops a clinical biomarker discovery platform. It engages in unraveling complex biology to find new ways to address disease. Its platform defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development. Genialis was established in 2015 in Boston, Massachusetts by Rafael Rosengarten.

Total Funding Amount:

$15.5M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)genialis.com

Founders:

Klemen Hrovat, Luka Ausec, Miha Stajdohar, Nejc Skoberne, Rafael Rosengarten

Number of Employees:

11-50

Last Funding Date:

2023-03-29

IPO Status:

Private

Industries: